These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26156591)

  • 1. A PBPK model describing a xenobiotic with a short PK event scale.
    Wang X; Davies BE
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):409-16. PubMed ID: 26156591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of PBPK modeling across the pediatric age range using propofol as a case.
    Michelet R; Van Bocxlaer J; Allegaert K; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):765-785. PubMed ID: 30298439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma.
    Brightman FA; Leahy DE; Searle GE; Thomas S
    Drug Metab Dispos; 2006 Jan; 34(1):84-93. PubMed ID: 16221757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
    Malmborg J; Ploeger BA
    J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases.
    Ryu HJ; Kang WH; Kim T; Kim JK; Shin KH; Chae JW; Yun HY
    Front Pharmacol; 2022; 13():964049. PubMed ID: 36034786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.
    Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):991-1000. PubMed ID: 24061863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics.
    Clewell HJ; Andersen ME
    Toxicol Ind Health; 1994; 10(1-2):1-24. PubMed ID: 7570610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.
    Lu G; Abduljalil K; Jamei M; Johnson TN; Soltani H; Rostami-Hodjegan A
    Curr Drug Metab; 2012 Jul; 13(6):695-720. PubMed ID: 22452453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma.
    Brightman FA; Leahy DE; Searle GE; Thomas S
    Drug Metab Dispos; 2006 Jan; 34(1):94-101. PubMed ID: 16221756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body physiologically based pharmacokinetic models.
    Nestorov I
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):235-49. PubMed ID: 17428153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan.
    Beaudouin R; Micallef S; Brochot C
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):103-16. PubMed ID: 20122977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.